Icon Plc

ICON plc is a contract research organization (CRO) providing outsourced development services on a global basis to pharmaceutical, biotechnology, medical device, and government and public health organizations. The company specializes in the strategic development, management, and analysis of programs supporting all stages of the clinical development process, from compound selection through Phase I-IV clinical studies. ICON offers services including clinical trials management, consulting, contract staffing, data services, and laboratory services, delivered either as standalone engagements or as part of integrated full-service or blended-service solutions. The company operates as a single reportable segment with approximately 40,200 employees across 99 locations in 55 countries. ICON derives its revenue roughly 26.5% from the United States, 61.2% from Europe, and 12.3% from Rest of World. Key recent strategic activity includes the disposal of its Symphony Health Solutions subsidiary to HealthVerity in exchange for equity, resulting in ICON holding a minority stake in HealthVerity. ICON's backlog of unsatisfied performance obligations stood at approximately $15.7 billion as of June 30, 2026. The company's capital structure includes a senior secured term loan and multiple series of senior secured notes totaling approximately $3.4 billion in principal, with a $500 million Bridge Secured Credit Facility drawn in July 2026 to repay maturing notes. The company is also subject to a consolidated securities class action lawsuit. ICON is incorporated in Ireland and listed on a U.S. exchange. Updated Jul 30, 2026